RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Identification of a potent human trace amine-associated receptor 1 antagonist
Decker, A. M., Brackeen, M. F., Mohammadkhani, A., Kormos, C. M., Hesk, D., Borgland, S. L., & Blough, B. E. (2022). Identification of a potent human trace amine-associated receptor 1 antagonist. ACS Chemical Neuroscience, 13(7), 1082-1095. https://doi.org/10.1021/acschemneuro.2c00086
Human trace amine-associated receptor subtype 1 (hTAAR1) is a G protein-coupled receptor that has therapeutic potential for multiple diseases, including schizophrenia, drug addiction, and Parkinson's disease (PD). Although several potent agonists have been identified and have shown positive results in various clinical trials for schizophrenia, the discovery of potenthTAAR1 antagonists remains elusive. Herein, we report the results of structure-activity relationship studies that have led to the discovery of a potent hTAAR1 antagonist (RTI-7470-44,34). RTI-7470-44 exhibited an IC50of 8.4 nM in anin vitrocAMP functional assay, aKiof 0.3 nMin a radioligand binding assay, and showed species selectivity for hTAAR1 over the rat and mouseorthologues. RTI-7470-44 displayed good blood-brain barrier permeability, moderate metabolicstability, and a favorable preliminary off-target profile. Finally, RTI-7470-44 increased the spontaneousfiring rate of mouse VTA dopaminergic neurons and blocked the effects of the known TAAR1 agonist RO5166017.Collectively, this work provides a promising hTAAR1 antagonist probe that can be used to study TAAR1 pharmacology and the potential therapeutic role in hypodopaminergic diseases such as PD
